NCT04668144View on ClinicalTrials.gov

Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI

PHASE4CompletedINTERVENTIONAL
Enrollment

359

Participants

Timeline

Start Date

February 18, 2021

Primary Completion Date

February 2, 2023

Study Completion Date

May 11, 2023

Conditions
Coronary Artery DiseaseAcute Coronary Syndrome
Interventions
DRUG

Cangrelor

Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The total infusion will last 2 hours.

DRUG

Prasugrel

Prasugrel will be used in line with FDA recommendations using a 60mg LD followed by a 10mg daily maintenance dose started 24 hours after LD administration

Trial Locations (1)

32209

University of Florida Jacksonville, Jacksonville

All Listed Sponsors
collaborator

Scott R. MacKenzie Foundation

OTHER

lead

University of Florida

OTHER

NCT04668144 - Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI | Biotech Hunter | Biotech Hunter